HIGHLY ACTIVE ANTIRETROVIRAL THERAPY Highly active
antiretroviral therapy (HAART) has changed the landscape of
HIV-related care in both the developed and developing countries.
The availability and widespread use of HAART has resulted
in a number of achievements as well as challenges. Since the
early days of antiretroviral therapy, adherence has emerged
a milestone to success. There are factors militating against
adherence to antiretroviral therapy among HIV-infected individuals
particularly in the resource - limited settings. Limited laboratory
infrastructure, lack of trained manpower and high cost of
laboratory monitoring test pose a major problem to implementing
HIV therapy in resource-poor settings. The disclosure of HIV
serostatus is a difficult emotional task creating opportunity
for support and rejection.
The second ICDDT to be held in Dubai in February 2010 will
address all areas pertinent to this endeavour, concentrating
on leads that arise from highly active antiretroviral therapy,
effect on the quality of life, Laboratory monitoring of patients
on HAART and HIV serostatus disclosure. There will be presentation
in varying subjects of Anaemia, Comparative analysis of malaria
parasite density using actual and assumed white blood cell
counts, Reference percentiles of haematological and biochemical
iron values of blood donors, Prostate cancer diagnosis, Anti-microbiological
drug resistance and other interesting topics in the area of
Biomedical Science. The list is not exhaustive and there will
be plenty of room for contributions that stem from other sources,
aiming to provide a well-informed and productive forum for
examination of as wide a range as possible of approaches developed
in disparate laboratories world-wide.
Erhabor Osaro
Royal Bolton Hospital NHS Foundation Trust
Bolton, UK
|
